Cited 0 times in
Protective Efficacy and Immunogenicity of Rv0351/Rv3628 Subunit Vaccine Formulated in Different Adjuvants Against Mycobacterium tuberculosis Infection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신성재 | - |
dc.contributor.author | 권기웅 | - |
dc.date.accessioned | 2023-07-12T02:56:52Z | - |
dc.date.available | 2023-07-12T02:56:52Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1598-2629 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195450 | - |
dc.description.abstract | Bacillus Calmette-Guerin (BCG) vaccine is the only licensed vaccine for tuberculosis (TB) prevention. Previously, our group demonstrated the vaccine potential of Rv0351 and Rv3628 against Mycobacterium tuberculosis (Mtb) infection by directing Th1-biased CD4+ T cells co-expressing IFN-γ, TNF-α, and IL-2 in the lungs. Here, we assessed immunogenicity and vaccine potential of the combined Ags (Rv0351/Rv3628) formulated in different adjuvants as subunit booster in BCG-primed mice against hypervirulent clinical Mtb strain K (Mtb K). Compared to BCG-only or subunit-only vaccine, BCG prime and subunit boost regimen exhibited significantly enhanced Th1 response. Next, we evaluated the immunogenicity to the combined Ags when formulated with four different types of monophosphoryl lipid A (MPL)-based adjuvants: 1) dimethyldioctadecylammonium bromide (DDA), MPL, and trehalose dicorynomycolate (TDM) in liposome form (DMT), 2) MPL and Poly I:C in liposome form (MP), 3) MPL, Poly I:C, and QS21 in liposome form (MPQ), and 4) MPL and Poly I:C in squalene emulsion form (MPS). MPQ and MPS displayed greater adjuvancity in Th1 induction than DMT or MP did. Especially, BCG prime and subunit-MPS boost regimen significantly reduced the bacterial loads and pulmonary inflammation against Mtb K infection when compared to BCG-only vaccine at a chronic stage of TB disease. Collectively, our findings highlighted the importance of adjuvant components and formulation to induce the enhanced protection with an optimal Th1 response. © 2023. The Korean Association of Immunologists. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Korea Society for Immunology : Korean Society of Biological Response Modifiers | - |
dc.relation.isPartOf | IMMUNE NETWORK | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Protective Efficacy and Immunogenicity of Rv0351/Rv3628 Subunit Vaccine Formulated in Different Adjuvants Against Mycobacterium tuberculosis Infection | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Microbiology (미생물학교실) | - |
dc.contributor.googleauthor | Kee Woong Kwon | - |
dc.contributor.googleauthor | Tae Gun Kang | - |
dc.contributor.googleauthor | Ara Lee | - |
dc.contributor.googleauthor | Seung Mo Jin | - |
dc.contributor.googleauthor | Yong Taik Lim | - |
dc.contributor.googleauthor | Sung Jae Shin | - |
dc.contributor.googleauthor | Sang-Jun Ha | - |
dc.identifier.doi | 10.4110/in.2023.23.e16 | - |
dc.contributor.localId | A02114 | - |
dc.relation.journalcode | J01033 | - |
dc.identifier.eissn | 2092-6685 | - |
dc.identifier.pmid | 37179749 | - |
dc.subject.keyword | Adjuvant | - |
dc.subject.keyword | BCG prime subunit booster | - |
dc.subject.keyword | Mycobacterium tuberculosis | - |
dc.subject.keyword | Th1 immune response | - |
dc.subject.keyword | Vaccine formulation | - |
dc.contributor.alternativeName | Shin, Sung Jae | - |
dc.contributor.affiliatedAuthor | 신성재 | - |
dc.citation.volume | 23 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | e16 | - |
dc.identifier.bibliographicCitation | IMMUNE NETWORK, Vol.23(2) : e16, 2023-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.